Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
- Author:
Weili ZHAO
1
;
Xuefeng WANG
;
Bin QU
;
Xiaping HUANG
;
Hongli WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Female; Humans; Lipoproteins; blood; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; blood; pathology; Receptors, Cell Surface; blood; Receptors, Urokinase Plasminogen Activator; Thromboplastin; metabolism; Urokinase-Type Plasminogen Activator; blood
- From: Chinese Medical Journal 2002;115(5):702-704
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo evaluate variations in the plasma tissue factor (TF) and urokinase type plasminogen activator (u-PA) system and their relationship with clinical cancer type, pathological classification and metastatic status in cancer patients.
METHODSPlasma levels of TF and its inhibitor (TFPI), as well as u-PA and its receptor (u-PAR) were measured using ELISA in 76 patients with malignant tumors and 24 patients with benign tumors.
RESULTSPlasma levels of TF and u-PAR in the malignant tumor group were significantly higher than those of the benign tumor group and the normal control. U-PA and u-PAR increased significantly in patients with esophageal and gastric cancer. However, most of these parameters except TFPI did not vary according to pathological classification. A significant elevation was evident in patients with local infiltration, lymph node involvement and distal metastasis, while u-PAR only increased in the latter two categories.
CONCLUSIONSBoth the TF and u-PA systems are activated in cancer patients. U-PA and its receptor might prove to be a clinically useful marker for disease progression.
